The use of lipid-lowering agents is suboptimal among dual enrollees, particularly blacks.
M edicare beneficiaries who are simultaneously enrolled in Medicaid, also known as dual enrollees, represent <14% of the Medicaid population, but their care accounts for 50% of total health care expenditures. 1, 2 More than one third of dual enrollees have diabetes and, compared with other Medicare beneficiaries with diabetes, dual enrollees are more than twice as likely to be hospitalized for diabetes complications. 1, 3 Cardiovascular disease is the leading cause of morbidity and mortality in diabetes, making management of cardiovascular risk factors such as hyperlipidemia a critical component of diabetes management. 4, 5 Clinical guidelines recommend the use of lipid-lowering agents for diabetes patients due to the potential for these agents to reduce adverse cardiovascular events. 6 However, the use of these agents among dual enrollees with diabetes is suboptimal. 7 Blacks, who are overrepresented among dual enrollees, have lower rates of use of lipid-lowering drugs than whites despite being at increased risk for death from heart disease. 1, 7, [8] [9] [10] [11] Out-of-pocket costs for lipid-lowering therapies have been identified as a significant barrier to guideline consistent treatment and as a potential determinant of disparities in use. 12 Historically, coverage for lipid-lowering and other prescription drugs was provided to dual enrollees through stateadministered Medicaid programs. The generosity of drug coverage through these programs has been highly variable, with several states (Texas, Oklahoma, Mississippi, Arkansas) imposing restrictive caps on the number of reimbursable prescriptions per month. [13] [14] [15] [16] [17] Drug caps have been associated with lower medication use and increase adverse events in vulnerable populations. [18] [19] [20] [21] The Medicare Modernization Act of 2003 required all dual enrollees to transition from Medicaid drug coverage to Medicare Part D, which disallowed the use of strict drug caps. 22, 23 Blacks are overrepresented among dual enrollees transitioning from Medicaid to Medicare Part D and are less likely to report having access to needed prescription medications under Part D. 24 Yet the impact of this major change in coverage for dual enrollees with diabetes on access to cardioprotective lipid-lowering therapies and disparities in the use of these agents is unknown.
Using the implementation of Medicare Part D as a natural experiment, we compared changes in the use of lipidlowering therapies among black and white dual enrollees living in states with and without restrictive drug caps. We hypothesized that the introduction of Part D would be associated with an increase in the use of lipid-lowering therapies. In addition, based on findings from an earlier prepost analysis of changes in overall medication use the Medicare population, we anticipated greater response among black dual enrollees, 25 resulting in a reduction in racial disparities in treatment in drug cap states. Although this paper focuses on the impact of this transition on January 1, 2006, such transitions are ongoing as disabled Medicaid beneficiaries who become eligible for dual Medicare enrollment after a required two-year waiting period and Medicaid beneficiaries who age into Medicare are automatically switched from Medicaid to Part D drug coverage. 22, 23 Therefore, findings from this analysis have the potential to inform strategies to facilitate the smooth transition of dual enrollees from Medicaid to Part D going forward. Moreover, the identification of potential differences in response to coverage changes by race have relevance to current health reform efforts to reduce disparities in health care through the expansion of health insurance coverage.
METHODS

Study Design
We used an interrupted time series with comparison series (ITS) cohort design to examine changes in use of lipidlowering drugs 24 months before and after the transition of dual enrollees from Medicaid to Medicare Part D drug coverage. As Part D affected all dual enrollees, there is no natural control group. Therefore, we exploited natural variation in the existence of drugs caps in state Medicaid programs to identify comparison groups of states based on exposure to drug caps before the introduction of Part D and heterogeneity of policy response among racial subgroups within strict drug cap and no drug cap states, respectively. We used longitudinal baseline data to allow each subgroup to act as its own control, comparing utilization after Part D to what we would have predicted in the absence of Part D, drawing on stable baseline trends. Assuming that state residency, although not random, is unrelated to the use of lipid-lowering therapy among diabetes patients, this natural experimental design should provide strong evidence of Part D effects.
Our study protocol was reviewed and approved by the Institutional Review Board of the Kaiser Foundation Research Institute.
Data Sources and Study Population
Using a merged dataset of a 5% nationally representative sample of linked Medicaid, Medicare, and Part D drug event standard analytic files for dual enrollees for the years 2004 through 2007 obtained from the Centers for Medicare and Medicaid Services, we identified fee-forservice beneficiaries who were at least 18 years old in 2004 and who had at least 1 hospital diagnosis or 2 physician diagnoses (no more than 12 mo apart) of diabetes (ICD-9: 250.XX) at any time during the study period (2004-2007) ( Fig. 1 ). We excluded enrollees residing in Ohio, Arizona, and Louisiana due to data anomalies in those states such as concurrent changes in coding and reporting methods. 26 The resulting study population included 60,288 adults with diabetes dually enrolled in fee-for-service (ie, excluding managed care) Medicaid and Medicare.
We further required continuous enrollment for at least 10 mo/y in both Medicaid and Medicare during the study period (n = 29,373) and no more than 90 consecutive days in any year in an institution such as a nursing home (n = 22,774; representing >455,000 dual enrollees nationwide).
State Restrictions on Prescription Drug Reimbursement before Part D
We assigned strict drug cap status to 4 states (Texas, Oklahoma, Mississippi, Arkansas) that consistently limited monthly drug coverage to r5 total prescriptions or to r3 brand name drugs during the 24-month baseline period, 2004-2005, and had no evidence of overrides or exceptions based on published summaries of drug benefits. [14] [15] [16] [17] [18] 27, 28 To reduce possible misclassification, we excluded from analysis 11 states (AL, CA, GA, IL, KS, KY, ME, NC, NY, PA, SC) where true exposure to drug caps was difficult to ascertain due to higher cap thresholds and generous waiver policies. In addition, we excluded Tennessee, which instituted a strict drug cap late in the baseline period. 15 We identified a comparison subgroup of dual enrollees who lived in 31 states (AK, CO, CT, DE, FL, HI, IA, ID, IN, MA, MD, MI, MN, MO, MT, ND, NE, NH, NJ, NM, NV, OR, RI, SD, UT, VA, VT, WA, WI, WV, WY) and the District of Columbia where there was no evidence of a prescription drug cap during the 24-month baseline period. Our final cohort for analysis included 8895 black and white diabetes patients living in either strict drug cap or no drug cap states.
Outcomes
Our primary outcomes were (1) the monthly proportion of patients with any use of lipid-lowering therapies (statins, niacin, bile-acid resins, fibric acid, derivatives, cholesterol absorption inhibitors); and (2) the intensity of use of these medications as represented by standardized monthly doses (SMDs), a validated measure used in previous policy evaluation studies. 19, 21, 22 We spread the days' supply of each lipid-lowering medication over the days following each dispensing; overlapping dispensing of the same medication was concatenated. We then created monthly indicators of any use for each patient based on the availability of a given medication on one or more days in a month, and we used these patient-specific measures to calculate monthly prevalence of use in each patient subgroup.
To assess intensity of use, we first defined an SMD 19, 22 for each generic entity of interest, which was equal to the median number of milligrams dispensed per month across person-months with any use during the entire study period. Thus, SMDs represent the population's "typical" monthly dose for a given medication. We then calculated average SMDs per patient per month (for specific drugs and by class) to evaluate changes in population intensity of use of lipidlowering agents over time, controlling for changes in prescription size. A key advantage of the SMD measure is that it allows for comparisons in the intensity of use across unique drug entities.
Policy Variables
We controlled for prior trends in the outcomes of interest using segmented time series regression, as described in previous studies. [19] [20] [21] [22] 29 We included a dichotomous indicator for months before and after Part D implementation, as well as a variable to estimate changes in after Part D trends. We identified state drug cap status in 2005 (strict drug cap vs. no drug cap) using a dichotomous indicator. Variation in Part D effect by drug cap status was evaluated by stratifying on the cap indicator and exploring interactions between it and the 2 Part D variables described above.
Covariates
We used Medicare administrative files to determine racial identity, age, and sex. Given higher rates of long-term disability among younger dual enrollees, we stratified all analyses by age: aged 65 or older (elderly) versus 18-65 years of age (nonelderly). Race and ethnicity data in these files are generated from Social Security Administration records based on social security card applications. Before 1980, the only options for race categorization were "white," "black," and "other," resulting in low and inaccurate capture of data on Hispanics and other racial and ethnic groups. 30 Although geocode-enhanced and surname-enhanced race and ethnicity data are now available to link to the 5% sample, these enhancements were not available throughout our study period. 31 Therefore, we included only patients with race designated as white or black, which are highly sensitive and specific. 30 To compare underlying health status across subgroups at baseline, we created patient-specific comorbidity scores using the hierarchical chronic conditions method employed by the Centers for Medicare and Medicaid Services for risk adjustment and service claims from 2005. 32 We also calculated the proportions of patients in each subgroup that year who had at least 1 hospital or 2 physician claims with a diagnosis of hypertension, and hospital claims related to diabetes, stroke, and ischemic heart disease.
Statistical Analysis
We used interrupted time series with comparison series to evaluate changes in the level and slope of the drug utilization outcomes, controlling for baseline trends. 33 We first estimated the overall impact of transitioning to Part D by cap status using separate ITS models for the nonelderly and elderly subgroups in both strict drug cap states and in the comparison group of no drug cap states, separately. We did not control for prior cardiovascular risk factors because lipidlowering therapy is recommended for all diabetes patients over 40 years. 6 Our data indicated a period of instability during the month before and 3 months following implementation of Part D, which may reflect anticipatory policy effects, data anomalies or some combination of factors that have the potential to bias study results. Therefore, we excluded observations generated during this brief, 4-month transition period (ie, December 2005-March 2006) from the models. The units of analysis were state-months, with 4 strict drug cap status states (treatment) and 32 no drug cap states (comparison group) and monthly data from 23 pre-2006 months and 21 post-2006 months, leading to 44 observations (23+21) in each group where the model is fitted. Our time series models controlled for autocorrelation by testing for first-order autoregressive processes and correcting for significant correlations. We also tested for nonlinearity of the models. 33 We directly evaluated the impact of Part D on racial gaps in the use of lipid-lowering drugs by modeling monthto-month white-black differences in use. 34 We stratified these ITS models by age, but not for cardiovascular risk as in the main models. Given higher levels of cardiovascularrelated disease among blacks at baseline, our models should represent conservative estimates of disparities. We then show the estimated white-black difference in the outcomes of interest at 1 year post intervention (April 2007) relative to what we would have expected based on prior trends. For models indicating evidence of an interaction between race and the policy effect variables, we further conducted race and age stratified, as well as race, age, and sex stratified models to explore the nature of the interaction.
To account for multiple testing, we applied a Bonferroni correction to reduce the likelihood of false positives. 35 For analyses of overall Part D impact and changes in the white-black gap, we conducted 8 independent tests, and P values of r0.006 were considered statistically significant. For race, age, and sex stratified models, we used a cut off of 0.004 to evaluate statistical significance to account for 12 independent tests. All statistical analyses were conducted using the SAS system (SAS, version.9.0; Durham, NC). 36 
RESULTS
Enrollee Characteristics
We identified 8895 black and white dual enrollees with diabetes living in strict drug cap (2175) and no drug cap states (6720) who met our study criteria (Table 1) . Compared with dual enrollees living in no drug cap states before Part D, dual enrollees in strict drug cap states were more likely to be black, nonelderly, and female. The proportions of dual enrollees using diabetes-related medications were similar across the 2 groups with the exception of use of insulin (drug cap: 28.4% vs. no drug cap: 32.1%) and lipid-lowering agents (drug cap: 54.0% vs. nondrug cap: 66.8%), both of which were more commonly used by dual enrollees in states without drug caps. In addition, dual enrollees in strict drug cap states were more likely to have comorbid hypertension (66.9% vs. 57.5%).
Within strict drug cap states (Table 1) , blacks were more likely than whites to be nonelderly, female, using insulin or any diabetes medication, have hypertension, and to be on antihypertensives. In no drug cap states, blacks were more likely to be elderly, female, have higher levels of comorbidity, including hypertension, to use diabetes and antihypertensive drugs, and to have higher rates of hospitalization for ischemic heart disease and stroke. However, use of lipid-lowering therapy was higher among whites compared with blacks in both strict drug cap (whites: 59.5%; blacks: 44.9%) and no drug cap states (whites: 68.4%; blacks: 61.9%). Figure 2 shows time series of changes in the proportion of dual enrollees using lipid-lowering therapies in strict and no drug cap states before and after Part D implementation. Among both nonelderly and elderly dual enrollees with diabetes living in strict drug cap states, the transition from Medicaid to Medicare Part D was associated with significant increases in the proportion of patients using lipid-lowering medications [nonelderly: 0.07 absolute percentage points (95% confidence interval, 0.05-0.09), P < 0.001; elderly: 0.08 (0.05-0.10), P < 0.001] ( Table 2 ). There was also an increasing trend in the proportion of patients with any use overtime in both age groups. In contrast, there were no statistically significant level shifts in use at the time of Part D implementation among those living in no drug cap states [nonelderly: À 0.001 (À 0.01 to 0.01), P = 0.749; elderly: À 0.01 (À 0.03 to 0.01), P = 0.205]. Similarly, the introduction of Part D was associated with increased intensity of use of lipid-lowering medications among both nonelderly and elderly dual enrollees in strict drug cap states [nonelderly: 0.09 SMDs (0.03-0.14), P = 0.002; elderly: 0.08 (0.03-0.12), P = 0.002] but not in no drug cap states [nonelderly: À 0.01 (À 0.03 to 0.005), P = 0.144; elderly: 0.002 (À 0.02 to 0.03), P = 0.842]. In addition, no drug cap states had a statistically significant (P < 0.001) decreasing trend in both the proportion of users [nonelderly: À 0.004 (À 0.005 to À 0.003); elderly: À 0.004 (À 0.005 to À 0.002)] and in the intensity of use [nonelderly: À 0.004 (À 0.01 to À 0.003); elderly: À 0.01(À 0.01 to À 0.004)] of lipid-lowering agents.
Changes in Use of Lipid-lowering Medications in Strict Drug Cap Versus No Drug Cap States
Racial Differences in Changes in Use of Lipid-lowering Medications after Part D
The results of models estimating the white-black gap in use of lipid-lowering medications, as well as estimated white-black differences in use at 12 months post policy implementation (April 2007) relative to what would have been expected given prior trends are presented in Table 3 . ITS models of monthly white-black differences did not produce statistically significant evidence of a change in the racial gap in the proportion of users, regardless of state drug cap status. We did, however, observe a slight, statistically significant declining trend in the white-black gap in the intensity of use post Part D among dual enrollees living in no drug cap states [nonelderly white-black gap: À 0.004 (À 0.01 to À 0.002), P < 0.001; elderly white-black gap: À 0.005 (À 0.007 to À 0.002), P < 0.001)].
Age-race stratified models of SMD for patients in no cap states (see Table, Supplemental Digital Content 1, http:// links.lww.com/MLR/A739) suggest that the primary driver of this change was a declining trend among whites [nonelderly: À 0.005 (À 0.01 to À 0.004); elderly: À 0.01 (À 0.01 to À 0.005)]. We further observed a small, statistically significant decrease in the level of intensity of use among nonelderly blacks [À 0.04 (À 0.06 to À 0.02), P = 0.001] in no drug cap states, that was not observed among whites. Further stratification by sex revealed that while the declining trend among whites was not sex specific, among blacks, only nonelderly men exhibited a declining trend in the intensity of use post policy [À 0.005 (À 0.01 to À 0.003); P < 0.001)]. In addition, the observed decrease in the level of intensity of use at the time of the policy among nonelderly blacks was primarily driven by changes among nonelderly black women [ À 0.04 (À 0.07 to À 0.02), P = 0.003].
CONCLUSIONS
Among fee-for-service dual enrollees with diabetes living in strict drug cap states with partial drug coverage, we found that the implementation of Part D was associated with abrupt increases in utilization of potentially life-saving lipidlowering medications compared with baseline trends that were not present in states without caps. In addition, we observed a sudden flattening of the upward baseline trend in the use of lipid-lowering therapy among dual enrollees in no cap states. These findings differ from previously published studies, 37, 38 which show no effect or minimal effects of Part D among dual enrollees. However, these prior studies did not adjust for state-level variation in the generosity of Medicaid coverage before Part D, which may have masked pockets of < 0.001 0.005 (0.004-0.005) < 0.001 À 0.001 (À 0.01 to 0.01) 0.749 À0.004 (À 0.005 to À 0.003) < 0.001 SMD 0.44 (0.43-0.46) < 0.001 0.01 (0.01-0.01) < 0.001 À 0.01 (À 0.03 to 0.005) 0.144 À0.004 (À 0.01 to À 0.003) < 0.001 Elderly Any 0.42 (0.41-0.43) < 0.001 0.004 (0.003-0.004) < 0.001 À 0.01 (À 0.03 to 0.01) 0.205 À0.004 (À 0.005 to À 0.002) < 0.001 SMD 0.48 (0.47-0.50) < 0.001 0.01 (0.01-0.01) < 0.001 0.002 (À 0.02 to 0.03) 0.842 À0.01 (À 0.01 to À 0.004) < 0.001 pent-up demand 39 within the larger population of patients. This pent-up demand effect may be stronger in our study due to the focus on lipid-lowering drugs, medications for which there is strong evidence of cost-related underuse and that are considered clinically essential medications for most adult patients with diabetes. 11 Slight declining trends in the use of lipid-lowering agents among dual enrollees in no cap states may be related to other changes in coverage related to Part D that were not the focus of this particular study. Specifically, those transitioning to private Part D plans from Medicaid may have faced other, somewhat less restrictive, forms of utilization management not addressed in this study (eg, prior authorization, copayments). 23 To our knowledge, this is one of the first studies to evaluate the impact of transitioning from Medicaid to Medicare Part D on disparities in use of clinically essential services. The removal of drug caps under Medicare Part D was not associated with an immediate narrowing of racial differences in the use of lipid-lowering therapy in strict cap states as we had hypothesized. Instead, we observed a declining trend in differences in the intensity of use among those in no drug cap states, particularly among whites regardless of sex or age. The decrease in the level of intensity of use among nonelderly black women in no drug cap states was also unexpected. However, these changes were relatively small in magnitude, potentially limiting their clinical significance.
Our findings in drug cap states suggest that disparities in essential medication use in this population may be due to factors other than coverage, such as racial differences in beliefs about the benefits and potential harms of therapy, differences in quality of care or prescribing practices across settings, overall medication burden due to higher rates of comorbid hypertension or differences in trust and patient engagement, including use self-management support services. 40 However, evidence of racial difference in response to the policy in no drug cap states were surprising and may be related to other aspects of Part D such as changes in exposure to prior authorization and other administrative cost containment strategies or unobserved co-occurring policies in these states.
Although this study focuses on patient utilization of lipid-lowering therapy, it is important to note that differential response to the policy by race may also reflect variation in physician response to policy change. In their role as prescribers, physicians can change prescribing practices in an effort to take advantage of expansions in coverage or to avoid administrative barriers to medication use. Yet, prior evidence suggests that physicians may be less likely to prescribe statins for black relative to white patients. 41 By extension, variation in physician advocacy based on patient characteristics such as race or characteristics of the settings where minority patients receive care may have contributed to the lower rates of beneficial policy effects in vulnerable population subgroups. More studies using data on prescribing physicians, settings of care, and patient-reported outcomes are needed to fully understand this and other potential drivers of heterogeneity in policy effects by race.
Several limitations deserve discussion. First, because all dual enrollees transitioned to Part D in January 2006, no true control group exists, which precludes a direct comparison of the effect between state drug cap subgroups, which varied considerably in underlying population characteristics at baseline. In addition, our decision to include only continuously enrolled patients to increase the stability of the underlying population also resulted in reduced the generalizability of our findings to dual enrollees who move in and out of coverage. A disadvantage of the ITS modeling strategy is that we could not control for confounders that occurred simultaneously with the policy, which are the only potential confounders of ITS designs. 33 We assumed that sudden changes in population-level characteristics such as severity of illness were highly unlikely. However, we could not control for unobservable local policy changes at the time of Part D implementation (eg, state-level efforts to educate Medicaid patients about the policy).
Our analysis of disparities is limited by the inaccuracy of racial and ethnic identifiers. Specifically, because of limited validity and reliability of race and ethnicity data during the study period, 31, 32 we excluded subgroups other than blacks and whites and did not further subset these groups by Hispanic ethnicity. Therefore, our analyses may mask subgroup differences based on ethnicity and do not necessarily extend to other racial groups that were excluded from this study.
Using a natural experiment, we found strong evidence that eliminating drug caps was associated with increasing the level and intensity of use of lipid-lowering agents among vulnerable dual enrollees with diabetes. However, racial disparities in the use of these agents persisted post Part D despite the removal of a significant coverage-related barrier to treatment. Targeted interventions to address non-coveragerelated barriers to the use of lipid-lowering therapy among blacks may be a necessary adjunct to ongoing policy-level efforts to reduce access-related treatment disparities in this highly vulnerable population. In addition, although the selected study design provided strong evidence of differential effects by race, age, and sex, alternative mixed methods designs may be needed to explore the contextual factors that drive variation in policy response.
